Clinical trial Recruiting at 1 site Observational Ages 15 to 38 Women only

Investigation of genetic factors in primary ovarian insufficiency

Official title: Insight Into the Genomics of Idiopathic Premature Ovarian Insufficiency

Run by Ospedale Policlinico San Martino · NCT05327283 · Data updated 2026-11-12

This study is trying to find out if certain genes play a role in primary ovarian insufficiency in women diagnosed before age 38, to improve future testing and treatment options.

More Premature Ovarian Insufficiency trials

Quick facts

Study typeObservational
Ages15 Years to 38 Years
SexWomen only
Enrollment100 (estimated)
SponsorOspedale Policlinico San Martino
Academic / other
Locations1 site (Genova)
StatusRecruiting
StartedJanuary 31, 2012
Main results expectedDecember 31, 2030
Study endsDecember 31, 2030
Registry record updatedApril 25, 2022
Trial IDNCT05327283 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are women diagnosed with primary ovarian insufficiency before the age of 38 who exhibit specific markers of diminished ovarian reserve.

Probably not a fit

Patients with POI related to conditions such as previous ovarian surgery, chemotherapy, or known autoimmune diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the genetic underpinnings of primary ovarian insufficiency (POI), a condition characterized by the premature depletion of ovarian follicles. By utilizing advanced genome-wide strategies such as high-resolution array-CGH and whole exome sequencing (WES), the researchers seek to identify genetic variants that contribute to the heterogeneity of POI. The study focuses on women diagnosed with POI before the age of 38, examining various markers of ovarian reserve to better understand the condition's biological mechanisms. The ultimate goal is to enhance testing and treatment strategies for affected women in the future.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic options for women suffering from primary ovarian insufficiency.

How similar studies have gone: While there have been studies investigating genetic factors in POI, this approach utilizing genome-wide strategies is relatively novel and aims to address unexplained aspects of the condition.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age at diagnosis \<38 years;
* a normal 46,XX karyotype (no FRM1 premutation);
* at least one marker of ovarian reserve not age-appropriate:

  * baseline FSH levels \> cut-off \[1\] and/or
  * age-specific AMH \< cut-off \[2\] and/or
  * AFC \< 5; and/or
* cancellation of a PMA cycle because of poor response (\<3 follicles) to high-dose gonadotrophins (250 U/die) and/or
* retrieval of \< 4 oocytes in response to high-dose stimulation protocols (3000 U of gonadotrophins).

Exclusion Criteria:

* patients with POI-related conditions, such as ovarian surgery or previous chemo- or radio-therapy; endometriosis or known autoimmune or metabolic diseases.

Where it's running

  • UOS Fisiopatologia della Riuproduzione Umana
    Genova, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.